SCHEMBL25412759

SCHEMBL25412759

Cc1ccc(S(=O)(=O)N2C[C@H](Cc3cccc(C(F)(F)F)c3)c3c(C=O)cccc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.44
▸ RORC P51449 4/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ LMNA P02545 3/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MAPT P10636 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ FFAR1 O14842 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCNA2 P20248 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ CDK7 P50613 1/20 0.37
▸ CCNH P51946 1/20 0.37
▸ CCNA1 P78396 1/20 0.37
▸ FFAR4 Q5NUL3 1/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25412765 1.00 GAA (0.44) GAARORCMEN1KMT2ALMNA
SCHEMBL25413077 0.91 GAA (0.43) GAARORCMEN1KMT2ALMNA
SCHEMBL25413083 0.91 GAA (0.43) GAARORCMEN1KMT2ALMNA
SCHEMBL25408807 0.89 CMA1 (0.46) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL25408804 0.89 CMA1 (0.46) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL25413763 0.88 ALDH1A1 (0.38) GAALMNASMN1; SMN2ALDH1A1POLB
SCHEMBL25413769 0.88 ALDH1A1 (0.38) GAALMNASMN1; SMN2ALDH1A1POLB
SCHEMBL25411441 0.86 ALDH1A1 (0.40) GAALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL25411450 0.86 ALDH1A1 (0.40) GAALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL25413834 0.86 KDM4E (0.39) LMNASMN1; SMN2ALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization MISSISSIPPI STATE UNIVERSITY 2023-09-07 — — US disclosed
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization MISSISSIPPI STATE UNIVERSITY 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization INMT, IDO2, WEE2 GAA 4101/4885RORC 351/4885MEN1 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback